In the Journals

Cross-linking for keratoconus may have best results in 18 to 39 age range

Corneal collagen cross-linking for progressive keratoconus improves functional and morphologic parameters, especially in patients between 18 and 39 years of age, according to a study.

Investigators evaluated morphologic and clinical outcomes of corneal collagen cross-linking for progressive keratoconus in different age groups.

The retrospective, single-center, nonrandomized clinical study included 400 eyes of 301 patients. Investigators analyzed best corrected visual acuity, sphere and cylinder refraction, corneal topography, Scheimpflug tomography and aberrometry at baseline and at 1, 6, 12, 24, 36 and 48 months after cross-linking.

Forty-nine eyes were between the ages of 9 and 17 years (group A), 185 eyes were between 18 and 29 years (group B), 115 eyes between 30 and 39 years (group C), and 51 eyes were older than 40 years (group D).

BCVA improved with a mean reduction of –0.11 logMAR after 12 months in group A, –0.31 logMAR after 36 months in group B,–0.33 logMAR after 36 months in group C and –0.26 logMAR after 36 months in group D. Morphologic results of corneal shape had a reduction of mean value by –0.53 at 12 months in group A, –1.14 at 36 months in group B, –1.10 at 36 months in group C and –0.55 at 12 months in group D.

Corneal collagen cross-linking for progressive keratoconus improves functional and morphologic parameters, especially in patients between 18 and 39 years of age, according to a study.

Investigators evaluated morphologic and clinical outcomes of corneal collagen cross-linking for progressive keratoconus in different age groups.

The retrospective, single-center, nonrandomized clinical study included 400 eyes of 301 patients. Investigators analyzed best corrected visual acuity, sphere and cylinder refraction, corneal topography, Scheimpflug tomography and aberrometry at baseline and at 1, 6, 12, 24, 36 and 48 months after cross-linking.

Forty-nine eyes were between the ages of 9 and 17 years (group A), 185 eyes were between 18 and 29 years (group B), 115 eyes between 30 and 39 years (group C), and 51 eyes were older than 40 years (group D).

BCVA improved with a mean reduction of –0.11 logMAR after 12 months in group A, –0.31 logMAR after 36 months in group B,–0.33 logMAR after 36 months in group C and –0.26 logMAR after 36 months in group D. Morphologic results of corneal shape had a reduction of mean value by –0.53 at 12 months in group A, –1.14 at 36 months in group B, –1.10 at 36 months in group C and –0.55 at 12 months in group D.